BioSpace News Archive

Boundless Bio today announced that it has appointed Neil Abdollahian, as Chief Business Officer.

Fluidigm Corporation today announced that company management will participate in the following investor event: UBS Genomics 2.0 and MedTech Innovations Summit Wednesday, August 11, 2021 Laguna Beach, California Panel presentation at 8:00 p.m. ET, 5:00 p.m. PT

Community Health Centers remain drivers of equity in the fight against COVID, despite the upsurge in the Delta variant

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the quarter ended June 30, 2021, and highlighted recent accomplishments.

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that Kirk Huntsman, Chief Executive Officer, Brad Amman, Chief Financial Officer and Ed Loew, Investor Relations Officer, will be presenting at the Q3 Virtual Investor Summit

Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced it will host a live webcast on Monday, August 16, 2021 at 8:30 a.m. ET to report its second quarter 2021 financial results and provide a business update.

Allakos Inc.Allakos Inc.Allakos Inc.Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell-related diseases, provided a business update and reported financial results for the second quarter ended June 30, 2021.

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, reported financial results for the three and six months ended June 30, 2021.

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announced a new credit agreement with Silicon Valley Bank, the lead agent, and several other lenders.

“We continued to deliver consistent growth and progress in the second quarter with the core NUZYRA commercial business seeing quarter over quarter growth, as net sales increased 13% to $14.9 million versus the first quarter,” said Evan Loh, M.D., Chief Executive Officer at Paratek.